We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Biomarkers Tested for Schizophrenia

By LabMedica International staff writers
Posted on 13 Mar 2014
Print article
Image: Laboratory scientists performing the VeriPsych Blood Test used to diagnose schizophrenia (Photo courtesy of MyriadRBM).
Image: Laboratory scientists performing the VeriPsych Blood Test used to diagnose schizophrenia (Photo courtesy of MyriadRBM).
Biochemical clues in the blood that signal severe psychiatric disorders are being investigated, but a large amount of time and effort are required to find definitive validated biomarkers.

Measuring changes in the cells or molecules of human tissues or fluids, by detecting so-called biomarkers, has aided the diagnosis of various diseases for some time, but when it comes to severe mental illnesses, such as schizophrenia, patients are just diagnosed by asking questions.

Scientists at the University of Cambridge (UK) have validated a blood serum test for diagnosing schizophrenia using samples from 572 schizophrenia patients and 235 healthy persons as control group. The final test consists of a so-called biomarker assay panel and includes 51 different proteins. The statistical analysis of the combination of these proteins yields results that give a probability that a patient is suffering from the disorder, and the test was able to correctly diagnose 83% of the schizophrenic patients and depression with a certainty of about 90%.

A test called VeriPsych (MyriadRBM; Austin, TX, USA) has been commercially available in the USA for about 18 months and has been ordered by 32 clinical centers, but the product needed further refinement to better fit the needs of patients and healthcare providers. A new European project has made excellent progress in achieving the goal of developing clinically useful biomarker tests for schizophrenia. Some of these blood-based markers based on previous studies could include interferon gamma, chromogranin A, and tissue inhibitor of metalloproteinases-1 (TIMP-1).

Following successful completion of the European project, Psynova Neurotech Ltd, RBM Inc. (Cambridge, UK) and EDI GmbH (Reutlingen, Germany) will seek to provide the early schizophrenia diagnostic assay panel as a commercially available clinical tool for psychiatrists and GPs by establishing the assays in a centralized screening laboratory. In addition, Psynova intends to offer the biomarker assay-panel products developed in this work as tools to aid the discovery and development of novel medicines for the treatment of schizophrenia.

Sabine Bahn, MD, PhD, MRCPsych, the head of the Cambridge Center for Neuropsychiatric Research (UK) said, “A blood-based biomarker test, additional to conventional clinical diagnosis, could enable earlier diagnosis and better treatment .We have so far identified blood biomarker signatures for distinguishing schizophrenia, bipolar disorder and depression and also for predicting drug response. The results from several patient cohorts are encouraging. There will now be larger prospective clinical trials.”

Related Links:
MyriadRBM
Psynova Neurotech Ltd, RBM 
EDI GmbH



Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Urine Drug Test
Instant-view Methadone Urine Drug Test
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more